Skip to main content
. 2021 Aug 24;107(1):e71–e83. doi: 10.1210/clinem/dgab617

Figure 1.

Figure 1.

Kisspeptin levels throughout pregnancy in women with hypertensive disorders of pregnancy (HDP) compared with control pregnancies and in women with fetal growth restriction (FGR) compared with control pregnancies. A, Scatterplot of medians (IQR) of multiples of gestation-specific median kisspeptin levels in healthy controls (red) (n = 265 women providing 898 samples) and women with HDP (blue) (n = 32 women providing 133 samples); groups were compared by Mann–Whitney U Test. B, Medians (IQR) of plasma kisspeptin levels in healthy controls (red) (n = 265 women providing 898 samples) and women with HDP (blue) (n = 32 women providing 133 samples) over the early and late first trimester, and second and third trimesters. Data were analyzed by Mann–Whitney U Test. C, Scatterplot of medians (IQR) of multiples of gestation-specific median kisspeptin levels in healthy controls (red) (n = 265 women providing 898 samples) and women with FGR (blue) (n = 17 women providing 56 samples); groups were compared by Mann–Whitney U Test. D, Medians (IQR) of plasma kisspeptin levels in healthy controls (red) (n = 265 women providing 898 samples) and women with FGR (blue) (n = 17 women providing 56 samples) over the early and late first trimester, and second and third trimesters. Data were analyzed by Mann–Whitney U Test.